Precision medicine to identify optimal diagnostic and therapeutic interventions for Parkinson's Disease

Main Article Content

Tarek Elshourbagy
Alveena Batool Syed
Mohamed A. M. Amer
James Robert Brasic

Abstract

Objective: Parkinson's disease, the second most common neurodegenerative disorder afflicting 10 million people worldwide and the fourteenth leading cause of death in the United States, is caused by the death of dopaminergic neurons that regulate movement in the substantia nigra pars compacta. Mechanisms contributing to the development of Parkinson’s disease in vulnerable individuals include protein misfolding, protein aggregation, and mitochondrial dysfunction. In order to develop guidelines for clinicians to utilize precision medicine to develop treatment plans to address the specific needs of individuals with Parkinson’s disease and related conditions, we have developed algorithms for diagnosis and treatment based on their view of available knowledge. We reviewed the key literature on the pathogenesis of Parkinson’s disease on PubMed and google scholar in order to propose guidelines for the development of diagnostic and therapeutic interventions for people with Parkinson’s disease and related conditions. In about 25 percent of patients, clinicians incorrectly diagnose Parkinson’s disease. Causes of misdiagnosis include a lack of algorithms and inadequate use of diagnostic modalities. Four main mechanisms that may contribute to the development of Parkinson's disease (misfolding of alpha-synuclein, mitochondrial dysfunction, dysfunctional ubiquitin proteasomal pathways, and abnormal autophagy) and different diagnostic modalities (structured interview and examination, laboratory assessments, neuropathology, genetic testing, neuroimaging) will form the basis for our algorithm for the diagnosis and treatment of Parkinson’s disease and related conditions. Clinicians, administrators, policy planners, advocates, and other concerned individuals will benefit from the adoption of our guidelines for the diagnosis and treatment of Parkinson’s disease and related conditions.

Downloads

Download data is not yet available.

Article Details

How to Cite
Elshourbagy, T., Syed, A. B., Amer, M. A. M., & Brasic, J. R. (2021). Precision medicine to identify optimal diagnostic and therapeutic interventions for Parkinson’s Disease. Medical Science and Discovery, 8(9), 514-519. https://doi.org/10.36472/msd.v8i9.595
Section
Review Article

References

1. Burré J, Vivona S, Diao J, Sharma M, Brunger AT, Südhof TC. Properties of native brain α-synuclein. Nature. 2013;498(7453):E4-6; discussion E6-7.

2. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011;108(10):4194–9.

3. Jung BC, Lim Y-J, Bae E-J, Lee JS, Choi MS, Lee MK, et al. Amplification of distinct α-synuclein fibril conformers through protein misfolding cyclic amplification. Exp Mol Med. 2017;49(4):e314–e314.

4. Kalia SK, Kalia LV, McLean PJ. Molecular chaperones as rational drug targets for Parkinson’s disease therapeutics. CNS Neurol Disord Drug Targets. 2010;9(6):741–53.

5. McKinnon C, Tabrizi SJ. The ubiquitin-proteasome system in neurodegeneration. Antioxid Redox Signal. 2014;21(17):2302–21.

6. McNaught KSP, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett. 2002;326(3):155–8.

7. Schlossmacher MG, Shimura H. Parkinson’s disease: assays for the ubiquitin ligase activity of neural Parkin. Methods Mol Biol. 2005;301:351–69.

8. Moon HE, Paek SH. Mitochondrial dysfunction in Parkinson’s disease. Exp Neurobiol. 2015;24(2):103–16.

9. Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci Transl Med. 2016;8(342):342ra78-342ra78.

10. Thomas B, Beal MF. Mitochondrial therapies for Parkinson’s disease: Mitochondria and Parkinson’s Disease. Mov Disord. 2010;25(S1):S155–60.

11. McKay GN, Harrigan TP, Brašić JR. A low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson’s disease. MethodsX. 2019;6:169–89.

12. Brasic J. Signal processing of quantitative continuous measurement of movements in the extremities. Mendeley; 2020.

13. Tao A, Chen G, Deng Y, Xu R. Accuracy of transcranial sonography of the substantia nigra for detection of Parkinson’s disease: A systematic review and meta-analysis. Ultrasound Med Biol. 2019;45(3):628–41.

14. Wang J, Liu Y, Chen T. Identification of key genes and pathways in Parkinson’s disease through integrated analysis. Mol Med Rep. 2017;16(4):3769–76.

15. Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578(7794):273–7.

16. Benamer HTS, Oertel WH, Patterson J, Hadley DM, Pogarell O, Höffken H, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations: Presynaptic Dopaminergic Imaging. Mov Disord. 2003;18(9):977–84.

17. Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [I123]β-CIT SPECT in clinical practice? Journal of Neurology, Neurosurgery and Psychiatry. 2005;76(9):1211–1216,.

18. Wang L, Zhang Q, Li H, Zhang H. SPECT molecular imaging in Parkinson’s disease. J Biomed Biotechnol. 2012;2012:412486.

19. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol. 1997;41(1):58–64.

20. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson’s disease: correlations with the three main symptoms. J Neurol Sci. 1996;136(1–2):169–73.

21. Gu S-C, Ye Q, Yuan C-X. Metabolic pattern analysis of 18F-FDG PET as a marker for Parkinson’s disease: a systematic review and meta-analysis. Rev Neurosci. 2019;30(7):743–56.

22. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease. J Neurol. 2000;247 Suppl 2:II11-8.

23. Cho SJ, Bae YJ, Kim J-M, Kim HJ, Baik SH, Sunwoo L, et al. Iron-sensitive magnetic resonance imaging in Parkinson’s disease: a systematic review and meta-analysis. J Neurol [Internet]. 2021; Available from: http://dx.doi.org/10.1007/s00415-021-10582-x

24. Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol. 2001;8(6):573–7.

25. LeWitt PA. Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics: Levodopa Pharmacokinetics and Pharmacodynamics. Mov Disord. 2015;30(1):64–72.

26. Radhakrishnan DM, Goyal V. Parkinson’s disease: A review. Neurol India. 2018;66(Supplement):S26–35.

27. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: A review: A review. JAMA. 2020;323(6):548–60.

28. Thakur P, Nehru B. Long-term heat shock proteins (HSPs) induction by carbenoxolone improves hallmark features of Parkinson’s disease in a rotenone-based model. Neuropharmacology. 2014;79:190–200.

29. Yoritaka A, Kawajiri S, Yamamoto Y, Nakahara T, Ando M, Hashimoto K, et al. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(8):911–6.

30. Gendelman HE, Zhang Y, Santamaria P, Olson KE, Schutt CR, Bhatti D, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. NPJ Parkinsons Dis [Internet]. 2017;3(1). Available from: http://dx.doi.org/10.1038/s41531-017-0013-5

31. Lee DJ, Dallapiazza RF, De Vloo P, Lozano AM. Current surgical treatments for Parkinson’s disease and potential therapeutic targets. Neural Regen Res. 2018;13(8):1342–5.

32. Olanow CW, Brin MF, Obeso JA. The role of deep brain stimulation as a surgical treatment for Parkinson’s disease. Neurology. 2000;55(12 Suppl 6):S60-6.

33. Wang L, Zhang Q, Li H, Zhang H. SPECT molecular imaging in Parkinson’s disease. J Biomed Biotechnol. 2012;2012:412486.

34. Loane C, Politis M. Positron emission tomography neuroimaging in Parkinson’s disease. Am J Transl Res. 2011;3(4):323–41.

35. Heim B, Krismer F, De Marzi R, Seppi K. Magnetic resonance imaging for the diagnosis of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):915–64. .

36. Jones DR, Moussaud S, McLean P. Targeting heat shock proteins to modulate α-synuclein toxicity. Ther Adv Neurol Disord. 2014;7(1):33–51